




<b>HUMANARZNEIMITTEL - EMA</b>	<b>2</b>
<i>Allgemeines – General</i>	2
<i>Pharmakovigilanz – PRAC</i>	2
<i>Zulassung – Regulatory Affairs</i>	3
<i>Orphan Drugs und neuartige Therapierichtungen (ATMP)</i>	5
<i>Qualität – Quality</i>	5
<i>(Prä-) Klinische Forschung – Research and Development</i>	6
<i>Kinderarzneimittel – Paediatrics</i>	7
<i>Pflanzliche Arzneimittel – Herbal medicines</i>	7
<b>EUROPEAN COMMISSION</b>	<b>9</b>
<b>EDQM</b>	<b>10</b>
<b>MEDIZINPRODUKTE</b>	<b>11</b>
<b>CMDH</b>	<b>12</b>
<b>HUMANARZNEIMITTEL - DEUTSCHLAND</b>	<b>13</b>
<b>HUMANARZNEIMITTEL - ÖSTERREICH</b>	<b>15</b>
<b>HUMANARZNEIMITTEL - SCHWEIZ</b>	<b>16</b>
 <b>FRAGEN AN DAS NETZWERK</b>	<b>17</b>
<b>VERANSTALTUNGEN / EVENTS – BEHÖRDEN UND ANDERE VERANSTALTER</b>	<b>18</b>
DEUTSCHLAND	18
ÖSTERREICH	18
SCHWEIZ	18
EUROPA	18
<u><a href="#">Urheberrechtshinweis:</a></u>	

Der MEGRA Newsletter und die darin enthaltenen Beiträge sind urheberrechtlich geschützt. Ohne die ausdrückliche Genehmigung der Urheber oder der Inhaber der Nutzungsrechte darf weder der MEGRA Newsletter noch Teile davon verbreitet, bearbeitet, öffentlich zugänglich, vorgetragen, in einem Abrufsystem gespeichert oder in ein solches eingeführt oder in einer beliebigen anderen Form (elektronisch, mechanisch, per Hyperlink, per Fotokopie, per Aufzeichnung oder auf anderem Wege) oder zu einem beliebigen anderen Zweck vervielfältigt oder übermittelt werden. Downloads und Kopien des Newsletters sind nur Mitgliedern der Mittel Europäischen Gesellschaft für Regulatory Affairs e.V. (MEGRA) und für den privaten, nicht kommerziellen Gebrauch gestattet. Durch das Herunterladen oder Kopieren von Inhalten werden keine Rechte bezüglich der Inhalte übertragen.

## Allgemeines – General

### **Supporting innovation**

**Published on:** 11 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/supporting-innovation>

### **Report - HMA/EMA Big Data Stakeholder Forum 2024**

**Published on:** 17 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/report/report-hma-ema-big-data-stakeholder-forum-2024\\_en.pdf](https://www.ema.europa.eu/en/documents/report/report-hma-ema-big-data-stakeholder-forum-2024_en.pdf)

### **Big data**

**Published on:** 17 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/how-we-work/biq-data>

### **European medicines agencies network strategy (EMANS) to 2028 webinar, Event 13 – February – 2025**

**Presentation and Video recording available**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/european-medicines-agencies-network-strategy-emans-2028-webinar>

### **Artificial intelligence**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/how-we-work/biq-data/artificial-intelligence>

### **Data Analysis and Real World Interrogation Network (DARWIN EU)**

**Published on:** 20 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/how-we-work/biq-data/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu>

## Pharmakovigilanz – PRAC

### **List of signals discussed at PRAC since September 2012**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/list-signals-discussed-prac-september-2012\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/list-signals-discussed-prac-september-2012_en.xlsx)

## Humanarzneimittel - EMA

### **Article 57 product data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/article-57-product-data\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx)

### **Union list of critical medicines: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPPD) / Product Management System (PMS) entries (outdated)**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/union-list-critical-medicines-extended-eudravigilance-medicinal-product-dictionary-xevmpd-product-management-system-pms-entries-outdated\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/union-list-critical-medicines-extended-eudravigilance-medicinal-product-dictionary-xevmpd-product-management-system-pms-entries-outdated_en.xlsx)

### **Referral: Finasteride- and dutasteride-containing medicinal products**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products>

## Zulassung – Regulatory Affairs

### **Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 27-30 January 2025**

**Published on:** 07 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-30-january-2025\\_en.pdf](https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-30-january-2025_en.pdf)

### **PRIME: priority medicines**

**Published on:** 07 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines>

### **Non-clinical Working Party**

**Published on:** 11 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/non-clinical-working-party>

### **Linguistic review – Human**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/linguistic-review-human>

## Humanarzneimittel - EMA

**Regulation (EU) 2024/568: Questions and answers clinic for the Human Industry stakeholders, Event 10 – February – 2025**

**Presentation available**

**Published on:** 13 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/regulation-eu-2024-568-questions-answers-clinic-human-industry-stakeholders>

**Training on human variations web-based electronic application form (eAF) functionalities for non-CAPs variations, Event 11 – February – 2025**

**Presentation and Video recording available**

**Published on:** 13 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/training-human-variations-web-based-electronic-application-form-eaf-functionalities-non-caps-variations>

**Substance and product data management services**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/data-medicines-iso-idmp-standards-overview/substance-product-organisation-referential-spor-master-data/substance-product-data-management-services>

**Union list of critical medicines**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/medicine-shortages-availability-issues/availability-medicines-during-crises/union-list-critical-medicines>

**Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages**

**Published on:** 17 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/contact-details-national-competent-authorities-requests-translation-exemptions-falling-under-art-633-directive-2001-83-ec-cases-shortages\\_en.pdf](https://www.ema.europa.eu/en/documents/other/contact-details-national-competent-authorities-requests-translation-exemptions-falling-under-art-633-directive-2001-83-ec-cases-shortages_en.pdf)

**International Coalition of Medicines Regulatory Authorities (ICMRA)**

**Published on:** 17 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/partners-networks/international-activities/multilateral-coalitions-initiatives/international-coalition-medicines-regulatory-authorities-icmra>

## Humanarzneimittel - EMA

**Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API), Event 04 – February – 2025**

**Video recording available**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/questions-answers-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-4-february-2025>

**Transfer of marketing authorisation: questions and answers**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/transfer-marketing-authorisation-questions-answers>

**Generic and hybrid applications**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/generic-hybrid-medicines/generic-hybrid-applications>

**Biosimilar medicines: marketing authorization**

**Published on:** 19 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/biosimilar-medicines-marketing-authorisation>

### Orphan Drugs und neuartige Therapierichtungen (ATMP)

**No news published**

### Qualität – Quality

**Product-specific bioequivalence guidance – Updated**

**Published on:** 12 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/product-specific-bioequivalence-guidance>

**ICH M12 on drug interaction studies - Scientific guideline**

**Published on:** 13 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/ich-m12-drug-interaction-studies-scientific-guideline>

## Humanarzneimittel - EMA

**Overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs - Scientific guideline**

**Published on:** 13 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/overview-current-regulatory-testing-requirements-medicinal-products-human-use-opportunities-implementation-3rs-scientific-guideline>

### (Prä-) Klinische Forschung – Research and Development

**ACT EU multi-stakeholder platform annual meeting, Event 22 – October – 2024**

**Meeting report and Video recording available**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/act-eu-multi-stakeholder-platform-annual-meeting>

**Records of data processing activity regarding the processing of personal data in the Clinical Trials Information System (CTIS)**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-processing-personal-data-clinical-trials-information-system-ctis\\_en.pdf](https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-processing-personal-data-clinical-trials-information-system-ctis_en.pdf)

**FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 - CTIS Training Programme - Module 01**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/faqs-introduction-clinical-trials-regulation-eu-no-536-2014-ctis-training-programme-module-01\\_en.pdf](https://www.ema.europa.eu/en/documents/other/faqs-introduction-clinical-trials-regulation-eu-no-536-2014-ctis-training-programme-module-01_en.pdf)

**Quick guide: How to search, view and download a Clinical Trial and a Clinical Trial Application (sponsors) - CTIS Training Programme - Module 09**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/quick-guide-how-search-view-download-clinical-trial-clinical-trial-application-sponsors-ctis-training-programme-module-09\\_en.pdf](https://www.ema.europa.eu/en/documents/other/quick-guide-how-search-view-download-clinical-trial-clinical-trial-application-sponsors-ctis-training-programme-module-09_en.pdf)

**Quick guide - Introduction: CTIS for SMEs and Academia - CTIS Training Programme - Module 19**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/quick-guide-introduction-ctis-smes-academia-ctis-training-programme-module-19\\_en.pdf](https://www.ema.europa.eu/en/documents/other/quick-guide-introduction-ctis-smes-academia-ctis-training-programme-module-19_en.pdf)

**Clinical Trial Information System (CTIS) - Sponsor handbook**

**Published on:** 19 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-sponsor-handbook\\_en.pdf](https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-sponsor-handbook_en.pdf)

# Humanarzneimittel - EMA

## **Development of the Clinical Trials Information System**

**Published on:** 20 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-sponsor-handbook\\_en.pdf](https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-sponsor-handbook_en.pdf)

## Kinderarzneimittel – Paediatrics

### **Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/members-coordinating-group-european-network-paediatric-research-european-medicines-agency-enpr-ema\\_en.pdf](https://www.ema.europa.eu/en/documents/other/members-coordinating-group-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf)

## Pflanzliche Arzneimittel – Herbal medicines

### **Herbal medicinal product: Boldi folium, C: ongoing call for scientific data**

**Published on:** 11 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/boldi-folium>

### **Herbal medicinal product: Anisi aetheroleum, C: ongoing call for scientific data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/anisi-aetheroleum>

### **Herbal medicinal product: Anisi fructus, C: ongoing call for scientific data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/anisi-fructus>

### **Herbal medicinal product: Centaurii herba, C: ongoing call for scientific data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/centaurii-herba>

### **Herbal medicinal product: Salviae officinalis folium, C: ongoing call for scientific data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/salviae-officinalis-folium>



## Humanarzneimittel - EMA

**Herbal medicinal product: Valerianae aetheroleum, C: ongoing call for scientific data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/valerianae-aetheroleum>

**Herbal medicinal product: Valerianae radix, C: ongoing call for scientific data**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/valerianae-radix>

**Herbal medicinal product: Combination: Hyperici herba, D: Draft under discussion**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/herbal/hyperici-herba>

**Procedures for monograph and list entry establishment**

**Published on:** 14 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/herbal-medicinal-products/procedures-monograph-list-entry-establishment>

**Interested Parties to the HMPC**

**Published on:** 17 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/hmpc-working-parties-other-groups/interested-parties-hmpc>



***Presentation and recording - EUHPP Live Webinar on European Health Data Space (1/3): Primary Use of health data and Electronic Health Record Systems, Event 18 – February – 2025***

***Published on: 20 - February - 2025***

***For more information, please refer to:***

***[https://health.ec.europa.eu/latest-updates/presentation-and-recording-euhpp-live-webinar-european-health-data-space-13-primary-use-health-data-2025-02-20\\_en](https://health.ec.europa.eu/latest-updates/presentation-and-recording-euhpp-live-webinar-european-health-data-space-13-primary-use-health-data-2025-02-20_en)***

***Certification monthly report of activities: End of January 2025***

***Published on: 12 - February - 2025***

***For more information, please refer to:***

***<https://www.edqm.eu/en/-/certification-monthly-report-of-activities-end-of-january-2025>***

## Medizinprodukte

**MDCG 2019-6 rev.5 - Questions and answers: Requirements relating to notified bodies (February 2025)**

**Published on:** 07 - February - 2025

**For more information, please refer to:**

[https://health.ec.europa.eu/latest-updates/mdcq-2019-6-rev5-questions-and-answers-requirements-relating-notified-bodies-february-2025-2025-02-07\\_en](https://health.ec.europa.eu/latest-updates/mdcq-2019-6-rev5-questions-and-answers-requirements-relating-notified-bodies-february-2025-2025-02-07_en)

**Guide to manufacturers on the procedure for requesting advice from expert panels on clinical investigations and / or clinical development strategies for high-risk medical devices**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/guide-manufacturers-procedure-requesting-advice-expert-panels-clinical-investigations-or-clinical-development-strategies-high-risk-medical-devices\\_en.pdf](https://www.ema.europa.eu/en/documents/other/guide-manufacturers-procedure-requesting-advice-expert-panels-clinical-investigations-or-clinical-development-strategies-high-risk-medical-devices_en.pdf)

**Medical devices**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices>

## **HMA Substances Validation Group Key documents**

**Published on:** 10 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/about-hma/working-groups/hma/hma-substances-validation-group.html#c7169>

## **EU-IN Introduction and Overview**

**Published on:** 18 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/about-hma/working-groups/eu-innovation-network-eu-in/eu-innovation-network-eu-in.html#c5500>

## **CTCG Introduction/Overview/Mandate**

**Published on:** 21 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7040>

# Humanarzneimittel - Deutschland

## **Expertengruppe Off-Label**

**Veröffentlicht am:** 10 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Zulassung/Zulassungsrelevante-Themen/Expertengruppe-Off-Label/artikel.html?nn=986770>

## **Spezialisierte Ethik-Kommission**

**Veröffentlicht am:** 12 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Spezialisierte-Ethik-Kommission/verteilerseite.html?nn=986770>

**Bekanntmachung nach § 35 Absatz 5a Sozialgesetzbuch (SGB) fünftes Buch (V) zu Änderungen in der Liste von Arzneimitteln, die auf Grund der zugelassenen Darreichungsformen und Wirkstärken zur Behandlung von Kindern notwendig sind (BANz AT 13.02.2025 B4)**

**Veröffentlicht am:** 13 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/amInformationen/Lieferengpaesse/Bekanntmachung\\_35Abs5a\\_sgb\\_v\\_stand\\_2025\\_02\\_13.html?nn=986770](https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/amInformationen/Lieferengpaesse/Bekanntmachung_35Abs5a_sgb_v_stand_2025_02_13.html?nn=986770)

## **CHMP Ausschuss für Humanarzneimittel**

**Veröffentlicht am:** 13 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Das-BfArM/EU-und-Internationales/CHMP-Ausschuss/artikel.html?nn=986770>

## **Häufig gestellte Fragen (FAQ) zur Zulassung**

**Veröffentlicht am:** 14 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/FAQ/Zulassung/artikel.html?nn=986770>

## **Arzneimittel-Lieferengpass-bekämpfungs- und Versorgungs-verbesserungs-gesetz (ALBVVG)**

**Veröffentlicht am:** 14 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/ALBVVG/artikel.html?nn=986770>

## **Meldeverpflichtungen**

**Veröffentlicht am:** 17 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Meldeverpflichtungen/artikel.html?nn=986770>

## **Informationen zu Einreichung und Genehmigung von Schulungsmaterial**

**Veröffentlicht am:** 17 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Schulungsmaterial/Zusatzinformationen/artikel.html?nn=986770>

# Humanarzneimittel - Deutschland

## **Maßnahmen des BfArM und ergänzende Informationen zu Lieferengpässen**

**Veröffentlicht am:** 18 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/_artikel.html?nn=986770)

## **Besonderheitenliste des BfArM**

**Veröffentlicht am:** 18 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Besonderheitenliste/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Besonderheitenliste/_artikel.html?nn=986770)

## **Aktuell laufende und bestätigte Arzneimittel-Härtefallprogramme**

**Veröffentlicht am:** 18 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/compUse-tabelle.html?nn=986770>

## **Arzneibuchkommissionen**

**Veröffentlicht am:** 19 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Zulassung/Zulassungsrelevante-Themen/Arzneibuch/Arzneibuchkommissionen/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Zulassung/Zulassungsrelevante-Themen/Arzneibuch/Arzneibuchkommissionen/_artikel.html?nn=986770)

## **PSUR Single Assessment (PSUSA)**

**Veröffentlicht am:** 18 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports\\_PSURs/PSUR-Single-Assessment/\\_artikel.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports_PSURs/PSUR-Single-Assessment/_artikel.html?nn=986770)

# Humanarzneimittel - Österreich

## **0225\_Bearbeitungsstand**

**Veröffentlicht am:** 10 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Gute Herstellungs- / Vertriebspraxis \(GMP/GDP\)](#)

## **Leitfaden: eService Zulassung und Lifecycle ASP (L\_Z55)**

**Veröffentlicht am:** 10 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[FAQ online Service](#)

[FAQ Online Service Zulassung & Lifecycle ASP](#)

## **CHMP Meeting Highlights Jänner 2025**

**Veröffentlicht am:** 12 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basq.gv.at/marktbeobachtung/amtliche-nachrichten/detail/chmp-meeting-highlights-jaenner-2025>

## **AGES-PHM-minimal-hoch**

**Veröffentlicht am:** 14 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Compassionate Use und Heilversuch/Named Patient Use](#)

## **Kontakt – updated: Weitere Regulatorische Ansprechpartner (L\_Z31)**

**Veröffentlicht am:** 18 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Kontakt](#)

## **PSUR outcome: Estradiol / Nomegestrolacetat**

**Veröffentlicht am:** 18 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Link zur Webseite der Europäischen Kommission](#)

## **0225\_Register bewilligter AM Betriebe Österreich**

**Veröffentlicht am:** 20 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Arzneimittelbetriebe](#)



## Humanarzneimittel - Schweiz

**Aktualisierung des Positionspapiers von Swissmedic und swissethics zu dezentralisierten klinischen Versuchen (DCTs) mit Arzneimitteln**

**Veröffentlicht am:** 10 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/clinical-trials/klinische-versuche-mit-arzneimitteln/publikationen.html>

**Swissmedic Portal Release Notes – 14.02.2025**

**Veröffentlicht am:** 17 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/services/eqov-services/smc-portal/release-notes/releae-note-170225.html>

**Überprüfung der Dokumentation zur Überwachung nach dem Inverkehrbringen durch Swissmedic**

**Veröffentlicht am:** 17 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/medizinprodukte/marktkontrolle-medinprodukte/schwerpunktaktionen/ueberpruefung-dokumentation-ueberwachung-nach-inverkehrbringen-smc.html>

**Aktualisierte Vorgabedokumente**

**Veröffentlicht am:** 19 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated\\_documents/feb-2025.html](https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents/feb-2025.html)



## Fragen an das Netzwerk

**Falls Sie eine Frage haben, die Sie gerne in unserem Netzwerk diskutieren würden, senden Sie uns einfach eine E-Mail an [info-as@megra.org](mailto:info-as@megra.org) zur anonymen Publikation im nächsten Newsletter.\***

\*Bei der Beantwortung der Fragen handelt es sich um eine Zusammenfassung von persönlichen Meinungen und Erfahrungswerten der MEGRA Mitglieder mit keinem Anspruch auf Rechtssicherheit. Wir empfehlen zur Absicherung die Konsultation entsprechender zugrunde liegender Regularien.

# Veranstaltungen / Events – Behörden und andere Veranstalter

## Deutschland

### **Workshop der Arbeitsgruppe Chemometrics and Quality Assurance zur Datenvisualisierung**

**Ort:** Paul-Ehrlich-Institut, Langen

**Termin:** 02 bis 03 - April - 2025

**Weitere Informationen finden Sie unter:**

<https://www.pei.de/SharedDocs/veranstaltungen-events/DE/2025/2025-04-02-gdch-workshop.html?nn=170994>

## Österreich

**Keine Veranstaltungen veröffentlicht**

## Schweiz

**Keine Veranstaltungen veröffentlicht**

## Europa

### **Training on human variations web-based electronic application form (eAF) functionalities for CAPs and non-CAPs variations**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 27 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/training-human-variations-web-based-electronic-application-form-eaf-functionalities-caps-non-caps-variations>

### **EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 05 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/ema-workshop-challenges-drug-development-regulation-clinical-practice-immunoglobulins>

### **Clinical Trials Information System (CTIS) bitesize talk: Change of sponsor in CTIS**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 05 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-bitesize-talk-change-sponsor-ctis>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Webinar on reflection paper on the qualification of non-mutagenic impurities**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 06 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/webinar-reflection-paper-qualification-non-mutagenic-impurities>

### **Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 06 & 13 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/qa-clinic-web-based-electronic-application-form-eaf-functionalities-caps-nons-caps-variations-0>

<https://www.ema.europa.eu/en/events/qa-clinic-web-based-electronic-application-form-eaf-functionalities-caps-nons-caps-variations>

### **DIA Europe 2025**

**Where:** Congress Centre Basel, Switzerland

**Date:** 18 to 20 - March - 2025

**For more information, please refer to:**

<https://www.edqm.eu/en/w/dia-europe-2025>

### **Clinical Trials Information System (CTIS) sponsor end user training programme - March 2025**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 25 to 28 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-sponsor-end-user-training-programme-march-2025>

### **Quarterly System Demo – Q1 2025**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 26 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/quarterly-system-demo-q1-2025>

### **EDQM Stakeholder Event on “Plasma Supply Continuity”**

**Where:** Congress Centre Basel, Switzerland

**Date:** 26 to 27 - March - 2025

**For more information, please refer to:**

<https://www.edqm.eu/en/plasma-supply-continuity>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### ***SPOR and XEVMPD status update webinar***

***Where:*** Live broadcast

***Date:*** 09 - April - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/spor-xevmpd-status-update-webinar>

### ***EMA Open Door Day***

***Where:*** European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 09 - May - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/ema-open-door-day>

### ***Product Management Service (PMS) information day 2025***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 21 - May - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/product-management-service-pms-information-day-2025>